Aripiprazole transdermal - Aequus Pharmaceuticals

Drug Profile

Aripiprazole transdermal - Aequus Pharmaceuticals

Alternative Names: AQS-1301; Transdermal aripiprazole - Aequus

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Transdermal Research Pharm Laboratories
  • Developer Aequus Pharmaceuticals; Corium International
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autistic disorder; Bipolar disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 28 Nov 2016 Aequus completes phase I clinical trials in Autistic disorder, Bipolar I disorder, Schizophrenia and Major depressive disorder (In volunteers) in Canada (Transdermal)
  • 17 Oct 2016 Aequus Pharmaceuticals submits CTA application with Health Canada
  • 17 Oct 2016 Aequus Pharmaceuticals plans a bioavailability study in volunteers in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top